Neuropharm - 2010 Biotech Graveyard
Company: Neuropharm
Based: United Kingdom
What Happened: Neuropharm's shares took a beating early last year after the biotech reported that its late-stage trial for an experimental autism therapy flunked its primary endpoint. Though its stock was revived upon rumors that it was getting close to a deal for NPL-2008, the deal never materialized. In April the developer opted for a voluntary liquidation, saying it would have sufficient funds to return money to its shareholders after paying creditors. There are no ongoing trials of NPL-2008.
Comments